Schedule of Investments (unaudited) October 31, 2020 | BlackRock Future Health ETF (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Common Stocks |
| |||||||
Biotechnology — 37.5% |
| |||||||
Acceleron Pharma Inc.(a) | 738 | $ | 77,180 | |||||
Agios Pharmaceuticals Inc.(a) | 1,038 | 41,593 | ||||||
Akeso Inc.(a)(b) | 6,000 | 18,801 | ||||||
Akouos Inc.(a) | 655 | 12,713 | ||||||
Alexion Pharmaceuticals Inc.(a) | 396 | 45,595 | ||||||
Allakos Inc.(a) | 524 | 49,848 | ||||||
Alnylam Pharmaceuticals Inc.(a) | 648 | 79,685 | ||||||
ALX Oncology Holdings Inc.(a) | 672 | 26,551 | ||||||
Amicus Therapeutics Inc.(a) | 1,044 | 18,614 | ||||||
Annexon Inc.(a) | 432 | 8,990 | ||||||
Apellis Pharmaceuticals Inc.(a) | 402 | 12,824 | ||||||
Applied Molecular Transport Inc.(a) | 390 | 11,462 | ||||||
Arcutis Biotherapeutics Inc.(a) | 366 | 6,522 | ||||||
Arena Pharmaceuticals Inc.(a) | 354 | 30,345 | ||||||
Argenx SE, ADR(a) | 282 | 69,973 | ||||||
Arrowhead Pharmaceuticals Inc.(a) | 198 | 11,345 | ||||||
Avidity Biosciences Inc.(a) | 864 | 21,367 | ||||||
Beam Therapeutics Inc.(a) | 396 | 13,531 | ||||||
Biohaven Pharmaceutical Holding Co. Ltd.(a) | 205 | 15,879 | ||||||
BioMarin Pharmaceutical Inc.(a) | 474 | 35,280 | ||||||
Blueprint Medicines Corp.(a) | 180 | 18,410 | ||||||
C4 Therapeutics Inc.(a) | 797 | 19,726 | ||||||
CareDx Inc.(a) | 534 | 26,193 | ||||||
ChemoCentryx Inc.(a) | 178 | 8,544 | ||||||
Cytokinetics Inc.(a) | 604 | 9,283 | ||||||
Deciphera Pharmaceuticals Inc.(a) | 192 | 11,149 | ||||||
Dicerna Pharmaceuticals Inc.(a) | 942 | 19,773 | ||||||
Eidos Therapeutics Inc.(a) | 282 | 19,999 | ||||||
Fate Therapeutics Inc.(a) | 264 | 11,722 | ||||||
FibroGen Inc.(a) | 378 | 14,508 | ||||||
Forma Therapeutics Holdings Inc.(a) | 1,272 | 54,849 | ||||||
Galecto Inc.(a) | 1,297 | 19,455 | ||||||
Genetron Holdings Ltd.(a) | 2,280 | 23,028 | ||||||
Genmab A/S(a) | 510 | 169,882 | ||||||
Genmab A/S, ADR(a) | 1,620 | 54,529 | ||||||
Global Blood Therapeutics Inc.(a) | 192 | 10,153 | ||||||
Grifols SA | 1,650 | 44,571 | ||||||
Immunovant Inc.(a) | 600 | 26,172 | ||||||
Intellia Therapeutics Inc.(a) | 342 | 8,187 | ||||||
Iovance Biotherapeutics Inc.(a) | 1,008 | 35,965 | ||||||
Kadmon Holdings Inc.(a) | 3,420 | 11,628 | ||||||
Karyopharm Therapeutics Inc.(a) | 954 | 14,138 | ||||||
Keros Therapeutics Inc.(a) | 498 | 27,689 | ||||||
Kodiak Sciences Inc.(a) | 420 | 38,140 | ||||||
Krystal Biotech Inc.(a) | 384 | 16,508 | ||||||
Kymera Therapeutics Inc.(a) | 636 | 22,890 | ||||||
Mersana Therapeutics Inc.(a) | 3,666 | 66,061 | ||||||
Mirati Therapeutics Inc.(a) | 213 | 46,251 | ||||||
Neurocrine Biosciences Inc.(a) | 408 | 40,257 | ||||||
Nkarta Inc.(a) | 990 | 28,423 | ||||||
ORIC Pharmaceuticals Inc.(a) | 462 | 9,933 | ||||||
PMV Pharmaceuticals Inc.(a) | 1,134 | 39,747 | ||||||
Praxis Precision Medicines Inc.(a) | 1,002 | 35,070 | ||||||
Prothena Corp. PLC(a) | 852 | 9,295 | ||||||
PTC Therapeutics Inc.(a) | 510 | 26,617 | ||||||
Rapt Therapeutics Inc.(a) | 444 | 12,761 | ||||||
Regeneron Pharmaceuticals Inc.(a) | 162 | 88,057 | ||||||
Retrophin Inc.(a) | 924 | 18,702 |
Security | Shares | Value | ||||||
Biotechnology (continued) | ||||||||
Sage Therapeutics Inc.(a) | 372 | $ | 27,297 | |||||
Sarepta Therapeutics Inc.(a) | 168 | 22,833 | ||||||
Seagen Inc.(a) | 1,170 | 195,156 | ||||||
Seres Therapeutics Inc.(a) | 876 | 24,432 | ||||||
Stoke Therapeutics Inc.(a) | 240 | 9,214 | ||||||
Taysha Gene Therapies Inc.(a) | 420 | 8,736 | ||||||
TCR2 Therapeutics Inc.(a) | 534 | 10,504 | ||||||
Twist Bioscience Corp.(a) | 570 | 43,685 | ||||||
United Therapeutics Corp.(a) | 138 | 18,524 | ||||||
Vertex Pharmaceuticals Inc.(a) | 205 | 42,714 | ||||||
Vir Biotechnology Inc.(a) | 312 | 9,809 | ||||||
Zai Lab Ltd., ADR(a) | 456 | 37,415 | ||||||
Zentalis Pharmaceuticals Inc.(a) | 534 | 21,141 | ||||||
Zymeworks Inc.(a) | 594 | 23,237 | ||||||
|
| |||||||
2,261,060 | ||||||||
Diversified Financial Services — 0.4% |
| |||||||
Eucrates Biomedical Acquisition Corp.(a) | 1,857 | 18,570 | ||||||
Helix Acquisition Corp.(a) | 445 | 4,570 | ||||||
|
| |||||||
23,140 | ||||||||
Health Care Equipment & Supplies — 27.7% |
| |||||||
ABIOMED Inc.(a) | 192 | 48,361 | ||||||
Alcon Inc.(a) | 1,830 | 104,017 | ||||||
Baxter International Inc. | 1,464 | 113,563 | ||||||
Cardiovascular Systems Inc.(a) | 396 | 14,117 | ||||||
Coloplast A/S, Class B | 48 | 7,005 | ||||||
ConvaTec Group PLC(b) | 10,962 | 25,612 | ||||||
Demant A/S(a) | 1,644 | 51,778 | ||||||
Eargo Inc.(a) | 400 | 13,860 | ||||||
Edwards Lifesciences Corp.(a) | 660 | 47,315 | ||||||
Envista Holdings Corp.(a) | 918 | 24,254 | ||||||
GN Store Nord A/S | 1,482 | 106,592 | ||||||
Haemonetics Corp.(a) | 648 | 65,506 | ||||||
Hill-Rom Holdings Inc. | 342 | 31,146 | ||||||
Insulet Corp.(a) | 336 | 74,676 | ||||||
Intuitive Surgical Inc.(a) | 174 | 116,072 | ||||||
Masimo Corp.(a) | 558 | 124,892 | ||||||
Nevro Corp.(a) | 588 | 87,736 | ||||||
NuVasive Inc.(a) | 324 | 14,395 | ||||||
Penumbra Inc.(a) | 264 | 68,912 | ||||||
Pulmonx Corp.(a) | 229 | 9,632 | ||||||
ResMed Inc. | 414 | 79,463 | ||||||
Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Class A | 900 | 51,987 | ||||||
Silk Road Medical Inc.(a) | 708 | 42,905 | ||||||
Sonova Holding AG, Registered(a) | 150 | 35,595 | ||||||
STERIS PLC | 324 | 57,410 | ||||||
Straumann Holding AG, Registered | 78 | 81,357 | ||||||
Tandem Diabetes Care Inc.(a) | 600 | 65,400 | ||||||
Teleflex Inc. | 336 | 106,925 | ||||||
|
| |||||||
1,670,483 | ||||||||
Health Care Providers & Services — 10.0% |
| |||||||
Addus HomeCare Corp.(a) | 102 | 9,952 | ||||||
Amedisys Inc.(a) | 540 | 139,860 | ||||||
Amplifon SpA(a) | 1,518 | 55,187 | ||||||
Centene Corp.(a) | 846 | 49,999 | ||||||
Chemed Corp. | 60 | 28,699 | ||||||
Encompass Health Corp. | 972 | 59,593 | ||||||
Humana Inc. | 192 | 76,662 | ||||||
Jinxin Fertility Group Ltd.(b) | 48,000 | 58,183 |
| 1 |
Schedule of Investments (unaudited) (continued) October 31, 2020 | BlackRock Future Health ETF (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Health Care Providers & Services (continued) | ||||||||
LHC Group Inc.(a) | 582 | $ | 126,032 | |||||
|
| |||||||
604,167 | ||||||||
Health Care Technology — 2.5% | ||||||||
American Well Corp., Class A(a) | 1,566 | 40,418 | ||||||
GoodRx Holdings Inc., Class A(a) | 162 | 7,839 | ||||||
Livongo Health Inc.(a)(c) | 480 | 67,090 | ||||||
Teladoc Health Inc.(a) | 174 | 34,184 | ||||||
|
| |||||||
149,531 | ||||||||
Insurance — 0.9% | ||||||||
eHealth Inc.(a) | 438 | 29,394 | ||||||
Selectquote Inc.(a) | 1,308 | 22,524 | ||||||
|
| |||||||
51,918 | ||||||||
Life Sciences Tools & Services — 10.8% | ||||||||
10X Genomics Inc., Class A(a) | 114 | 15,607 | ||||||
Avantor Inc.(a) | 1,800 | 41,886 | ||||||
Berkeley Lights Inc.(a) | 798 | 57,911 | ||||||
Charles River Laboratories International Inc.(a) | 216 | 49,183 | ||||||
Gerresheimer AG | 366 | 36,793 | ||||||
Illumina Inc.(a) | 84 | 24,587 | ||||||
IQVIA Holdings Inc.(a) | 342 | 52,665 | ||||||
Lonza Group AG, Registered | 84 | 50,883 | ||||||
PPD Inc.(a) | 3,996 | 131,388 | ||||||
WuXi AppTec Co. Ltd., Class H(b) | 6,000 | 95,553 | ||||||
Wuxi Biologics Cayman Inc.(a)(b) | 3,500 | 97,758 | ||||||
|
| |||||||
654,214 | ||||||||
Pharmaceuticals — 7.7% | ||||||||
Astellas Pharma Inc. | 2,400 | 32,944 | ||||||
Atea Pharmaceuticals Inc. | 535 | 16,232 | ||||||
Chugai Pharmaceutical Co. Ltd. | 700 | 26,925 | ||||||
Eisai Co. Ltd. | 200 | 15,475 | ||||||
Hansoh Pharmaceutical Group Co. Ltd.(a)(b) | 24,000 | 106,927 | ||||||
Harmony Biosciences Holdings Inc.(a) | 228 | 8,869 |
Security | Shares | Value | ||||||
Pharmaceuticals (continued) | ||||||||
Horizon Therapeutics PLC(a) | 396 | $ | 29,672 | |||||
Merck KGaA | 468 | 69,316 | ||||||
MyoKardia Inc.(a) | 90 | 20,118 | ||||||
Nektar Therapeutics(a) | 834 | 13,211 | ||||||
Relmada Therapeutics Inc.(a) | 618 | 19,115 | ||||||
Royalty Pharma PLC, Class A | 336 | 12,331 | ||||||
UCB SA | 918 | 90,572 | ||||||
|
| |||||||
461,707 | ||||||||
|
| |||||||
Total Common Stocks — 97.5% | 5,876,220 | |||||||
|
| |||||||
Short-Term Investments | ||||||||
Money Market Funds — 2.3% | ||||||||
BlackRock Cash Funds: Treasury, SL Agency Shares, 0.04%(d)(e) | 140,000 | 140,000 | ||||||
|
| |||||||
Total Short-Term Investments — 2.3% | 140,000 | |||||||
|
| |||||||
Total Investments in Securities — 99.8% | 6,016,220 | |||||||
Other Assets, Less Liabilities — 0.2% | 14,906 | |||||||
|
| |||||||
Net Assets — 100.0% | $ | 6,031,126 | ||||||
|
|
(a) | Non-income producing security. |
(b) | Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. |
(c) | Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. |
(d) | Affiliate of the Fund. |
(e) | Annualized 7-day yield as of period-end. |
Affiliates
Investments in issuers considered to be affiliate(s) of the Fund during the period ended October 31, 2020 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
Affiliated Issuer | Value at 09/29/20(a) | Purchases at Cost | Proceeds from Sales | Net Realized Gain (Loss) | Change in Unrealized Appreciation (Depreciation) | Value at 10/31/20 | Shares Held at 10/31/20 | Income | Capital Gain Distributions from Underlying Funds | |||||||||||||||||||||||||||
BlackRock Cash Funds: Treasury, SL Agency Shares | $ | — | $ | 140,000 | (b) | $ | — | $ | — | $ | — | $ | 140,000 | 140,000 | $ | 6 | $ | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
(a) | The Fund commenced operations on September 29, 2020. |
(b) | Represents net amount purchased (sold). |
Fair Value Measurements
Various inputs are used in determining the fair value of financial instruments. For description of the input levels and information about the Fund’s policy regarding valuation of financial instruments, refer to a recently published shareholder report. Shareholder reports are available on the Fund’s website at iShares.com and on the U.S. Securities and Exchange Commission website at sec.gov.
2 |
|
Schedule of Investments (unaudited) (continued) October 31, 2020 | BlackRock Future Health ETF |
Fair Value Measurements (continued)
The following table summarizes the value of the Fund’s investments according to the fair value hierarchy as of October 31, 2020. The breakdown of the Fund’s investments into major categories is disclosed in the Schedule of Investments above.
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Investments | ||||||||||||||||
Assets | ||||||||||||||||
Common Stocks | $ | 5,809,130 | $ | — | $ | 67,090 | $ | 5,876,220 | ||||||||
Money Market Funds | 140,000 | — | — | 140,000 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
$ | 5,949,130 | $ | — | $ | 67,090 | $ | 6,016,220 | |||||||||
|
|
|
|
|
|
|
|
The following table includes a rollforward for the period ended October 31, 2020 of investments whose values are classified as Level 3 as of the beginning or end of the period.
Common Stocks | ||||
Balance at beginning of period(a) | $ | — | ||
Realized gain (loss) and change in unrealized appreciation/depreciation | 506 | |||
Purchases | 66,584 | |||
Sales | — | |||
Transfers in | — | |||
Transfers out | — | |||
|
| |||
Balance at end of period | $ | 67,090 | ||
|
| |||
Net change in unrealized appreciation/depreciation on investments still held at end of period | $ | 506 | ||
|
|
(a) | The Fund commenced operations on September 29, 2020. |
The Fund’s investments that are categorized as Level 3 were valued utilizing a single broker quote without adjustment. Such valuations are based on unobservable inputs. A significant change in third party information could result in a significantly lower or higher value of such Level 3 investments.
Portfolio Abbreviations - Equity
ADR American Depositary Receipt
| 3 |